

# Pharmacy and Therapeutics Committee Meeting

## Agenda

600 East Broad Street – 7<sup>th</sup> Floor Conference Rooms

Richmond, Virginia 23219

February 9, 2010 - 10:00 a.m.

### DRAFT AGENDA

Welcome and Comments	Patrick Finnerty, DMAS Director
Call to Order	Randy Axelrod, M.D., Chairman
Approval of Minutes From October 22, 2009 Meeting	P&T Committee Members
PDL Management	P&T Committee Members

- **Potential New Therapeutic Class Review (PDL Category)**
  - ◆ **Insulins (Diabetes)**
  - ◆ **Injectable Hypoglycemic Agents** including incretin enhancers/mimetics (Diabetes)
  - ◆ **Androgenic Agents (Endocrine and Metabolic agents this is a potential new category)**
  - ◆ **Platelet Inhibitors (Cardiac Medications)**
  
- **PDL Phase II – New Drug Review (Therapeutic Class)**
  - ◆ **Twynsta® (Angiotension II Receptor Blockers and Calcium Channel Blocker Combination)**
  
- **PDL Phase II – Annual Review**
  - ◆ **Analgesics**
    - Long Acting Narcotics
    - Non-Steroidal Anti-Inflammatory Drugs (NSAID) (includes Cox-2 Inhibitors)
  - ◆ **Antibiotics/Anti-infective**
    - 2<sup>nd</sup> and 3<sup>rd</sup> Generation Cephalosporins
    - 2<sup>nd</sup> and 3<sup>rd</sup> Generation Quinolones (systemic)
    - Ketolides
    - Macrolides
    - Oral Antifungals for Onychomycosis
    - Otic Quinolones
    - Topical Antibiotics
  - ◆ **Antivirals**
    - Herpes Antivirals
    - Influenza Antivirals
    - Topical Antivirals
  - ◆ **Asthma- Allergy**
    - Intranasal Antihistamines
    - Leukotriene Formation Inhibitors
    - Leukotriene Modifiers
  - ◆ **Central Nervous system**
    - Antihyperkinesis/CNS Stimulants
    - Non-Ergot Dopamine Receptor Agonists
  - ◆ **Dermatologic**
    - Benzoyl Peroxide and Clindamycin combinations
    - Topical Agents For Psoriasis
    - Topical Retinoids and combinations

- **PDL Phase II – Annual Review (continued)**
  - ◆ **Immunologic agents**
    - Multiple Sclerosis Agents
    - Self Administered Drugs For Rheumatoid Arthritis
  - ◆ **Ophthalmics**
    - Alpha-2 Adrenergic (for treatment of glaucoma)
    - Antihistamines
    - Beta-blockers (for treatment of glaucoma)
    - Carbonic Anhydrase Inhibitors (for treatment of glaucoma)
    - Mast Cell Stabilizers
    - Nonsteroidal Anti-Inflammatory (NSAID)
    - Prostaglandin Analogs (for treatment of glaucoma)
    - Quinolones and Macrolides
  - ◆ **Oral Hypoglycemics**
    - 2<sup>nd</sup> Generation Sulfonylureas
    - Alpha-Glucosidase Inhibitors
    - Biguanides including combination products
    - DPP-IV Inhibitors and combination products
    - Meglitinides
    - Thiazolidinediones and combination products
  - ◆ **Osteoporosis**
    - Bisphosphonates
    - Calcitonins
  - ◆ **Miscellaneous**
    - Serotonin Receptor Agonists (Triptans)

**Confidential Meeting**

- **Pricing Information Discussion**

**P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8**

**Criteria Discussion of Potentially New Classes\*\***

**P&T Committee Members**

**Criteria Discussion of Phase I New Drugs\*\***

**P&T Committee Members**

**Criteria Discussion of PDL Phase II Drug Classes\*\***

**P&T Committee Members**

**Next Meeting – April 22, 2010**

**Randy Axelrod, M.D., Chairman**

*\*\*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

**Oral Presentations:** The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes subject to PDL Phase II annual review, potential new drug classes, and specific new drugs in PDL Phase I classes listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase II Annual Review – February 2009 to present
- New Drugs in PDL Phase I Drug Classes – February 2008 to present
- Potential New Drug Classes – February 2008 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) **by close of business Tuesday, January 19, 2010.**

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) **by close of business Tuesday, January 19, 2010.**